Teva resumes acquisitions with $900 million Emalex deal after decade-long hiatus

Teva will pay $700 million upfront and up to $200 million more for Emalex, which develops a Tourette syndrome treatment granted orphan drug status; the deal comes as the company reports $4 billion in quarterly revenue and $369 million in net profit, beating forecasts

Raccontata daynetnews.com